Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes
EndocrinologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Diabetes care
- Publicado em
- 1 dez 2025
- Citações
- 3
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes
Timothy E Graham, Dan Raghinaru, Samina Afreen, Andrew Ahmann, Ahmad Haidar, Philip Raskin, Michael A Tsoukas, John W Lum, Ravid Sasson-Katchalski, Jordan E. Pinsker et al.
Descritores MeSH
- Hypoglycemic Agents
- Insulin
- Insulin Infusion Systems
- Diabetes Mellitus, Type 2
- Glucagon-Like Peptide-1 Receptor Agonists
- Glycated Hemoglobin
- Humans
- Male
- Middle Aged
- Adult
Veja também
Estudos relacionados
- Efficacy and Safety of Automated Insulin Delivery in People With Type 2 Diabetes: A Systematic Review and Meta-Analysis
- Comparison of GLP-1 Receptor Agonists, SGLT-2 Inhibitors, and DPP-4 Inhibitors as an Add-On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review
- Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
- A Multicentre, Randomised, Controlled, Open-Label Study of Continuous Subcutaneous Insulin Infusion Plus Henagliflozin for Treating Type 2 Diabetes Mellitus Patients With Severe Hyperglycaemia
- Benefício consistente do controle- QI+ Entrega automática de insulina numa gama de características de adultos com diabetes tipo 2